Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink Partners Global Biopharma Conference Call March 11, 2024 4:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Resear...

Vertex Pharmaceuticals' positives include strong profitability and multiple growth drivers. The stock doesn't have the negatives of nosebleed valuation, intense competition, or super-high risk.

Vertex brought in more than $9.8 billion last year thanks to its flagship cystic fibrosis drugs. The company is moving closer to the finish line with a new cystic fibrosis treatment that may even b...

Vertex plans on submitting its pain candidate to regulators by mid-year. A young biotech company just announced it's working on a very similar pain candidate.

Vertex's P/S ratio is very high, relative to most other biopharma stocks. It's important, though, to look to the future rather than the past when considering the company's valuation.

Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for ...

Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.

Vertex Pharmaceuticals' acute pain candidate was not as impressive as hoped in a late-stage study. Still, the drugmaker has an excellent lineup and multiple highly promising pipeline candidates.

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2023 Earnings Call Transcript

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.20 per share, beating the Zacks Consensus Estimate of $4.10 per share. This compares to earnings of $3.76 per share a year ago.

Vertex Pharmaceuticals experimental triple combination cystic fibrosis (CF) treatment met all late-stage study goals when tested in patients aged 12 years and older, the company said on Monday.

Vertex's cystic fibrosis portfolio has been a raging success for the company. The biotech's next potential product addresses the extremely common problem of pain -- and could become its next blockb...

Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.

Beyond analysts' top -and-bottom-line estimates for Vertex (VRTX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quart...